Rilonacept

Drug Profile

Rilonacept

Alternative Names: Arcalyst; IL-1 Trap; IL-1 Trap - Regeneron; Interleukin-1 antagonist - Regeneron; Interleukin-1 Trap - Regeneron; RGN 303

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Caspase 1 inhibitors; Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryopyrin-associated periodic syndromes
  • Discontinued Anaemia; Cardiovascular disorders; Gout; Juvenile rheumatoid arthritis; Osteoarthritis; Polymyalgia rheumatica; Rheumatoid arthritis

Most Recent Events

  • 27 Mar 2015 Regeneron has patent protection for rilonacept in USA
  • 23 Oct 2013 Biomarkers information updated
  • 12 Nov 2012 Regeneron Pharmaceuticals terminates the phase III UPSURGE trial in Gout in USA (NCT01459796)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top